SCHEMBL16109293

SCHEMBL16109293

O=C1Nc2ccc(Br)cc2C(c2ccccc2)O1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.53
GAA P10253 1/20 0.44
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TP53 P04637 4/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.40
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381944 0.82 CA2 (0.53) CA2GAAALDH1A1POLBMAPT
SCHEMBL10959402 0.79 CA2 (0.51) CA2GAAL3MBTL1MAPTLMNA
SCHEMBL3378813 0.78 ALDH1A1 (0.48) CA2ALDH1A1L3MBTL1CYP1A2POLB
SCHEMBL19411809 0.76 PIK3CD (0.45) GAAALDH1A1NPSR1L3MBTL1CYP1A2
SCHEMBL4167925 0.76 PGR (0.54) CA2GAAMAPT
SCHEMBL19805150 0.75 PDE3B (0.42) GAATP53POLBMAPTLMNA
SCHEMBL3308855 0.75 ALDH1A1 (0.64) CA2GAAALDH1A1CYP1A2CYP2C9
SCHEMBL28871521 0.73 CA2 (0.51) CA2GAAALDH1A1CYP1A2CYP2C9
SCHEMBL16109538 0.72 BRD4 (0.69)
SCHEMBL14094474 0.71 SIRT2 (0.66) GAAALDH1A1NPSR1L3MBTL1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2978758-B1 DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-02-08 EP disclosed
EP-2978758-B1 DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-02-08 EP disclosed
EP-2978758-A1 DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS Boehringer Ingelheim International GmbH (DE) 2016-02-03 EP disclosed
US-9199988-B2 Dihydroquinazolinone analogues BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-12-01 US disclosed
US-9199988-B2 Dihydroquinazolinone analogues BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-12-01 US disclosed
US-20140296230-A1 DIHYDROQUINAZOLINONE ANALOGUES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-02 US disclosed
US-20140296230-A1 DIHYDROQUINAZOLINONE ANALOGUES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-02 US disclosed
WO-2014154762-A1 DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-02 WO disclosed
WO-2014154762-A1 DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296230-A1 DIHYDROQUINAZOLINONE ANALOGUES MKI67, NQO2, CCNI CA2 3150/4885GAA 673/4885ALDH1A1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.